GSK Set for $500 Million Payment From mRNA Lawsuit Settlement

Biotech Law | Intellectual Property | Business Litigation Introduction: A Settlement Years in the Making In a significant resolution to one of the most closely watched biotechnology IP battles, CureVac NV has reached a settlement with Pfizer Inc. and BioNTech SE over allegations of patent infringement related to mRNA vaccine technology.